2002, Number 2
<< Back Next >>
Rev Endocrinol Nutr 2002; 10 (2)
Pie diabético
García GE
Language: Spanish
References: 10
Page: 84-88
PDF size: 98.07 Kb.
ABSTRACT
In the last decade the natural history of diabetic foot has been described in detail. Identification of
key role events in the pathway to amputation has been useful to design prevention strategies.
Early and systematic treatment of common mycosis is effective to prevent severe infections. New
antibiotics administered p.o. or by permanent catheters in the ambulatory set are useful to improve
and cure infectious problems otherwise destined to amputation approach. Magnetic Resonance
(MR) is a very good tool to establish osteomyelitis diagnosis, it is also useful to follow up the
answer to antibiotic treatment in all those candidate cases.
REFERENCES
Moss SE, Klein R, Klein BEK. The 14 year incidence of lowerextremityamputations in a diabetic population. TheWisconsin epidemiologic study of diabetic retinopathy. DiabetesCare 1999; 22: 951-959.
Edmonds ME. Progress in care of the diabetic foot. TheLancet 1999; 354: 270-272.
Heald AH, O’Halloran DJ, Richards K, Webb F, Jenkins S,Hollis S, Denning DW, Young RJ. Fungal infection of thediabetic foot: two distinct syndromes. Diabetic Medicine2001; 18: 567-572.
Litzelman DK, Slemenda ChW, Langfeld CD, Hays LM, WelchMA, Bild DE, Ford ES, Vinicor F. Reduction of lower extremityclinical abnormalities in patients with non-insulin-dependentdiabetes mellitus. Annals of Internal Medicine 1993; 119:36-41.
Ollendorf DA, Kotsanos JG, Wishner WJ, Friedman M,Cooper T, Bittoni M, Oster G. Potential economic benefitsof lower-extremity amputation prevention strategies in diabetes.Diabetes Care 1998; 21: 1240-1245.
Craig JG, Amin MB, Wu K, Eyler WR, van Holsbeeck MT,Bouffard JA, Shirazi K. Osteomyelitis of the diabetic footMR imaging-pathologic correlation. Radiology 1997; 203:849-855.
Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topicalgel formulation of recombinant human platelet derived growthfactor-BB (Becaplermin) in patients with chronic neuropathicdiabetic ulcers. Diabetes Care 1998; 21: 822-827.
Faglia E, Favales F, Aldegib A, Calia P, Quarantiello A, OrianiG, Miachael M, Campagnoli P, Morabito A. Adjunctivesystemic hyperbaric oxygen therapy in treatment of severeprevalently ischemic diabetic foot ulcer. Diabetes Care 1996;19: 1338-1343.
Jorneskog G, Brismar K, Fagrell B. Skin capilary circulationis more impaired in the toes of diabetic than non-diabeticpatients with peripheral vascular disease. Diabetic Medicine1995; 12: 36-41.
Rosemblum BI, Pomposelli FB Jr, Giurini JM, Gibbons GW,Freeman DV, Chrzan JS, Campbell DR, Habershaw GM, LoGerfo FW. Maximizing foot salvage by a combinedapproach to foot ischemic and neuropathic ulceration inpatients with diabetes. A 5-year experience. Diabetes Care1994; 17: 983-987.
Full text